Remember this article by him (11/6/12) prior to ACAD results in Nov 2012...-
Acadia said top-line results from the pimavanserin phase III study in Parkinson's disease psychosis (PDP) would be announced this month, reiterating it's previous timing guidance.
But if Acadia is optimistic about pimavanserin's chances, why did the company sell stock so cheaply in the September quarter?
But if the study fails, investors shredded by Acadia's plummeting stock price will look back at the ATM sale and curse themselves for not heeding the warning.
-- Reported by Adam Feuerstein in Boston.
Lets see if you had followed his cautious note you would have sold ACAD stock under $2 and missed the run-up to mid 20's.......